Irritable Bowel Syndrome (IBS)NCT02651532
Confocal Endomicroscopy Utility (p-CLE) in Irritable Bowel Syndrome
An observational study of Irritable Bowel Syndrome (IBS), run by Instituto Ecuatoriano de Enfermedades Digestivas at 1 site in Ecuador.
Trial summary
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. It has prevalence in general population of 5-20% and is more common in women and young adults. Despite being one of the most frequent reasons for consultation many patients are undiagnosed. There are no reliable biomarkers. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Irritable Bowel Syndrome (IBS)
- What is being tested?
- Confocal Laser Endomicroscopy
- Type of treatment
- Medical device
- How many people
- 74 participants
- Where
- 1 siteEcuador
- Study dates
- Jan 2016to Mar 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: 1) Improvement with defecation, 2) Start associated with changes in the bowel frequency, 3) Start associated with changes in stool consistency. In the absence of alarm symptoms. It will be measured in all patients serology for celiac disease, serum thyroid-stimulating hormone (TSH) and parasitological test. It will be done, in high suspicion patients, stool culture, breath test for lactose intolerance and breath test for bacterial overgrowth.
Who may be able to join
- Above 18 years old patients
- Who agree to participate in the study
- Ability to provide written informed consent
- Patients with irritable bowel syndrome according to Roma III classification.
Who cannot join
- Patients, who were receiving nonsteroidal anti-inflammatory drugs, corticosteroids or antibiotics in the last 4 weeks.
- Patients with heart disease, kidney, liver or severe metabolic disorder, who cannot tolerate sedation
- Inflammatory bowel disease
- Bacterial overgrowth
- Gastrointestinal bleeding
- Prior history of any king of colitis (actinic, infectious, ischemic, microscopic colitis)
Show all 13Show fewer
- Suspected colonic obstruction or history of previous obstruction
- Prior history of colectomy surgery
- Patients with an ileostomy or a colostomy
- Patients with difficulty understanding instructions of bowel preparation
- Known allergy to fluorescein or shellfish
- Pregnancy and lactation
- Bowel preparation will be evaluated using the Boston Bowel Preparation Scale. (9) Patients with < 2 points in at least one of the three segments of the colon (rectum plus left-side colon, transverse colon plus left and right flexure, right-side colon) will be excluded from statistical analysis as well as those who after the beginning of the colonoscopy, had to be aborted because of an inability to reach the cecum by unfavorable anatomy or impassable tumors / stenosis.
Trial locations and contacts
1 site in 1 country.
Ecuador1 site
Ecuadorian Institute of Digestive Diseases
Guayaquil, Guayas, 090505
About this study
Official title: Confocal Endomicroscopy Utility for Diagnosing Mucosa Micro-inflammation in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. It has prevalence in general population of 5-20% and is more common in women and young adults.
Despite being one of the most frequent reasons for consultation many patients are undiagnosed. There are no reliable biomarkers. The diagnosis is clinical, based on the Rome III criteria. IBS is characterized by chronic or recurrent abdominal pain associated with changes in bowel frequency and consistency, when other etiologies are excluded. The combination of the Rome III criteria with the absence of alarm symptoms have a sensitivity of 65%, specificity of 100%, 100% positive predictive value and negative predictive value of 76%.
Current tests commonly fail to obtain an objective diagnosis, and effective therapies are lacking. There are no specific endoscopic findings that can discriminate IBS patients from healthy patients. Most colonoscopies are performed to rule out other etiologies and in more than 50% of the cases are normal.
Read the detailed description
The pathophysiology is complex, multifactorial and not completely known. Impaired intestinal barrier function and mucosal inflammation in the small and large intestine have been reported. Evidence of inflammation and neuronal degeneration in the myenteric plexus has been found in full-thickness intestinal biopsy samples from IBS patients.
It has been found that IBS patients had a significantly higher density of intestinal epithelial gaps. The elevated epithelial gaps in the intestine of IBS patients, a surrogate marker for increased epithelial cell extrusion, may be a cause of altered intestinal permeability observed and may lead to mucosal inflammation.
Confocal laser endomicroscopy (CLE) is a new endoscopic imaging tool enabling visualization of changes in the gut mucosa. The use of intravenous fluorescein enables high-resolution real-time imaging in vivo at a micron scale, allowing visualization of cellular details during ongoing endoscopy. This technology can be used to identify and quantify epithelial gaps and other signs of inflammation.
The purpose of this study is to evaluate the presence of microscopic inflammation previously demonstrated in patients with IBS, using pCLE. The determination of the exact areas of inflammation allows a direct biopsy in a more accurate way. This type of systematic may allow in the future to classify these patients not only symptomatically (constipation, diarrhea or mixed predominant IBS) but also according to their degree of inflammation. There is no Gold Standard test in these patients to assess response to treatment. The possibility of using pCLE to identify the areas of microscopic inflammation allows that the degree of inflammation can be used as a monitoring parameter. Probably the CLE can be used to assess response to treatment and different types of treatments, determining differences between subtypes of patients with IBS, evaluate remission, recurrence and prognosis. Also it may clarify a potential mechanism of the pathogenesis and be endoscopic criteria for the diagnosis of the disease.
The present study is the first to evaluate the colon microscopic inflammation using pCLE in IBS patients.
Study design: This is an observational and analytical cross-section, population - based survey study, with prospective case collection, non-randomized and simple blind, performed in a Tertiary Academic Center.
Setting: Ecuadorian Institute of Digestive Diseases (IECED), OmniHospital Academic Tertiary Center. We will include patients from October 2015 to March 2016. Patients will be recruited from the gastroenterology unit (IECED). The study protocol and consent form has been approved by the Institutional Review Board (IRB) and will be conducted according to the declaration of Helsinki. Patients will sign an informed consent and answer a questionnaire that includes constitutional data (sex, age, comorbid medical condition, medication). Patients in IBS group will be classified according to the symptoms as diarrhea predominant (IBS-D), constipation predominant (IBS-C) or mixed type (IBS-M). Endoscopic findings will be recorded in a database.
Endoscopic technique: All colonoscopies will be performed after the patient had undergone standard bowel preparation using either polyethylene glycol electrolyte lavage solution. Initially a routine white light colonoscopy will be performed in IBS and healthy control patients, using a Pentax scope (Pentax EC-387CILK, Tokyo, Japan) with great care not to damage the epithelium. The Boston Bowel Preparation Scale and inflammation changes will be recorded.
During withdrawal, all parts of the colon will be evaluated (cecum, right-side colon, transverse, left-side colon, sigmoid and rectum) using pCLE randomly in one point of each segment, if there are no signs of iatrogenic mucosal damage. Careful washing of the mucosa with water in order to prevent the inclusion of image artefacts from residual stool fragments. Before initiating CLE evaluation, intravenous injection of 5 ml 10% fluorescein will be done. Fluorescein stains vessels and gives good tissue structure, but the nuclei are not stained and appear as dark spots. Optimal contrast is obtained within the first 10min after injection, but good quality images can be acquired for a further 30-60 min.
Currently Confocal Laser Endomicroscopy (CLE) is performed using a CLE probe (pCLE). The confocal microscope used in pCLE captures microscopic images of untreated in vivo tissue. The microscope uses focused laser light of a defined wavelength and passes it through a confocal aperture. Images are then reconstructed in two dimensions. For pCLE (Cellvizio by Mauna Kea Technologies, Paris, France), both the laser scanning unit and light source are outside the body. The laser beam is transported via flexible confocal miniprobes and a distal lens sequentially scans it through a bundle of more than 10000 optical fibers. Confocal miniprobes are flexible, with diameters ranging from 0.9 mm to 2.5 mm.
In the study a pCLE ColoFlex probe will be used (Cellvizio; Mauna Kea Technology, Paris, France). The probe goes through the accessory channel of a conventional endoscope. The image rate is 0.08 s/frame at 1024×1024 pixels with a imaging depth of 20 μm. The confocal images will be first analyzed during the endoscopy. Then, the images will be digitally stored and reviewed after the procedure in order to zoom in on details for a higher magnification (approximately 10000 fold), with special designed software package (Cellvizio Viewer), allowing image correction and stabilization.
Immediately after pCLE evaluation, and before proceeding to the next colon segment, targeted biopsies will be taken from the mucosal area evaluated. Bleeding can impair image quality, therefore probe will be placed gently in contact with the tissue in order to avoid trauma and pCLE imaging will be completed in a region before mucosa biopsy. The endoscopist performing the pCLE will be blinded to the status of the patient and the images will be later analyzed in detail blindly by two different persons with more than two years' experience in endomicroscopy.
There are not studies that validate a classification of colon inflammation using CLE in IBS patients. Inflammation of the colon mucosa in ulcerative colitis (UC) has been described previously using CLE. Kiesslich et al. reported on a 3-grade classification of inflammation activity by CLE, combining crypt architecture, cellular infiltrations, and vessel architecture. Nevertheless the assessment of cellular infiltration has been questioned because of the difficulty in differentiating cell types by CLE. Chang-Qing Li, et al. used three CLE parameters to evaluate inflammation in UC patients: a 4-grade crypt-architecture classification, fluorescein leakage, and microvascular alterations. On the other hand, the Miami classification for pCLE defines colitis using: crypt fusion and distortion, bright epithelium, dilated and prominent branching vessels.In the present study the parameters used for CLE inflammation will be: 1.Epithelial gaps followed by leaks with secretion of fluorescein into the lumen. In CLE images of normal colonic mucosa, the lumen of the crypt is free of fluorescein and appears as a dark center in the crypt; however, in inflamed mucosa, fluorescein leaks into the crypt lumen; therefore, the lumen is brighter than the surrounding epithelium. 2.4-grade crypt-architecture classification: Types A and B will be considered as normal and chronic inflammation, respectively, and types C and D indicate acute inflammation. Type A: Regular arrangement and size of crypts. Type B: Irregular arrangement of crypts, enlarged spaces between crypts. Type C: Dilation of crypt openings, more irregular arrangement of crypts, and enlarged spaces between crypts as compared to type B. Type D: Crypt destruction and / or crypt abscess. 3.Dilated and prominent branching vessels
Interobserver and Intraobserver Agreement: A data set containing CLE photographs and videos of the all of the colon segments will be presented to three blinded endoscopists, who will confirm or not the findings. Inter- and intra-observer reproducibility will be measured based on comparison of still images and videos between the three investigators. To evaluate the intra-observer agreement each investigator will assess the images two times and the answers will be compared. To evaluate the inter-observer agreement all answers between the three investigators will be compared. In general, the learning curve of CLE is short and inter or intra-observer agreement is good.
Statistical analysis: Baseline characteristics will be compared between case and control group using Chi-square o Fisher Test for categorical variable, and for continuing variables, we will use the Mann-Whitney Test. Diagnosis efficacy will be measured thought sensitive, specificity and accuracy. All the statistical analysis will be performed using SPSS software suite v.22.
- Conditions
- Irritable Bowel Syndrome (IBS)
- Being tested
- Confocal Laser Endomicroscopy
- Keywords
- Confocal Laser Endomicroscopy, inflammation, Irritable Bowel Syndrome
- Medical subject headings
- Irritable Bowel Syndrome, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Confocal Laser EndomicroscopyDevice
During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
| Study group | Role | What they receive |
|---|---|---|
| IBS + Confocal Laser Endomicroscopy | Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test. Receives: Device: Confocal Laser Endomicroscopy | |
| Control + Confocal Laser Endomicroscopy | Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening Receives: Device: Confocal Laser Endomicroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Confocal Laser Endomicroscopy (CLE) utility for diagnosing microscopic inflammation of the mucosa in patients with irritable bowel syndrome (IBS)
Number of patients with IBS and microscopic inflammation determinate by CLE
Measured: four month
Secondary outcomes (1)
Relationship between microscopic inflammation and sex, age and the subtypes of IBS.
Number of patients with microscopic inflammation according to sex, age and the subtypes of IBS.
Measured: four month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jan 2016 (estimated)
- Study startJan 2016
- Primary completionMar 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Irritable Bowel Syndrome (IBS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 74 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Carlos A Robles-Medranda, MD, Principal investigator, Ecuadorian Institute of Digestive Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02651532
- Sponsor's protocol ID
- ENE12016
- Status last verified
- Nov 2018
- First submitted
- 7 Jan 2016
- Last updated
- 20 Nov 2018
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Publications
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061.
PubMed 16678561Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available.
PubMed 16678553Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008 Apr 17;358(16):1692-9. doi: 10.1056/NEJMcp0801447.
PubMed 18420501Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31. doi: 10.1053/gast.2002.37095. No abstract available.
PubMed 12454866Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):1972-9. doi: 10.1053/gast.2002.37059.
PubMed 12454854Kiesslich R, Goetz M, Angus EM, Hu Q, Guan Y, Potten C, Allen T, Neurath MF, Shroyer NF, Montrose MH, Watson AJ. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology. 2007 Dec;133(6):1769-78. doi: 10.1053/j.gastro.2007.09.011. Epub 2007 Sep 16.
PubMed 18054549Turcotte JF, Kao D, Mah SJ, Claggett B, Saltzman JR, Fedorak RN, Liu JJ. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc. 2013 Apr;77(4):624-30. doi: 10.1016/j.gie.2012.11.006. Epub 2013 Jan 26.
PubMed 23357497Fritscher-Ravens A, Schuppan D, Ellrichmann M, Schoch S, Rocken C, Brasch J, Bethge J, Bottner M, Klose J, Milla PJ. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1012-20.e4. doi: 10.1053/j.gastro.2014.07.046. Epub 2014 Jul 30.
PubMed 25083606Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):620-5. doi: 10.1016/j.gie.2008.05.057. Epub 2009 Jan 10.
PubMed 19136102Kuiper T, Kiesslich R, Ponsioen C, Fockens P, Dekker E. The learning curve, accuracy, and interobserver agreement of endoscope-based confocal laser endomicroscopy for the differentiation of colorectal lesions. Gastrointest Endosc. 2012 Jun;75(6):1211-7. doi: 10.1016/j.gie.2012.01.040. Epub 2012 Mar 28.
PubMed 22459661Wallace M, Lauwers GY, Chen Y, Dekker E, Fockens P, Sharma P, Meining A. Miami classification for probe-based confocal laser endomicroscopy. Endoscopy. 2011 Oct;43(10):882-91. doi: 10.1055/s-0030-1256632. Epub 2011 Aug 4.
PubMed 21818734Becker V, von Delius S, Bajbouj M, Karagianni A, Schmid RM, Meining A. Intravenous application of fluorescein for confocal laser scanning microscopy: evaluation of contrast dynamics and image quality with increasing injection-to-imaging time. Gastrointest Endosc. 2008 Aug;68(2):319-23. doi: 10.1016/j.gie.2008.01.033. Epub 2008 Apr 24.
PubMed 18436217Kiesslich R, Goetz M, Lammersdorf K, Schneider C, Burg J, Stolte M, Vieth M, Nafe B, Galle PR, Neurath MF. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007 Mar;132(3):874-82. doi: 10.1053/j.gastro.2007.01.048. Epub 2007 Jan 31.
PubMed 17383417Li CQ, Xie XJ, Yu T, Gu XM, Zuo XL, Zhou CJ, Huang WQ, Chen H, Li YQ. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol. 2010 Jun;105(6):1391-6. doi: 10.1038/ajg.2009.664. Epub 2009 Nov 24.
PubMed 19935787
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Confocal Endomicroscopy Utility for Diagnosing Mucosa Micro-inflammation in Patients With Irritable Bowel Syndrome
- ClinicalTrials.gov ID
- NCT02651532
- Acronym / sponsor ID
- ENE12016
- Conditions
- Irritable Bowel Syndrome (IBS)
- Keywords
- Confocal Laser Endomicroscopy, inflammation, Irritable Bowel Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 74 participants (actual)
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades DigestivasUniversity, hospital or other
- Study start
- Jan 2016
- Primary completion
- Mar 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 11 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders. It has prevalence in general population of 5-20% and is more common in women and young adults.
Despite being one of the most frequent reasons for consultation many patients are undiagnosed. There are no reliable biomarkers. The diagnosis is clinical, based on the Rome III criteria. IBS is characterized by chronic or recurrent abdominal pain associated with changes in bowel frequency and consistency, when other etiologies are excluded. The combination of the Rome III criteria with the absence of alarm symptoms have a sensitivity of 65%, specificity of 100%, 100% positive predictive value and negative predictive value of 76%.
Current tests commonly fail to obtain an objective diagnosis, and effective therapies are lacking. There are no specific endoscopic findings that can discriminate IBS patients from healthy patients. Most colonoscopies are performed to rule out other etiologies and in more than 50% of the cases are normal.
Detailed description
The pathophysiology is complex, multifactorial and not completely known. Impaired intestinal barrier function and mucosal inflammation in the small and large intestine have been reported. Evidence of inflammation and neuronal degeneration in the myenteric plexus has been found in full-thickness intestinal biopsy samples from IBS patients.
It has been found that IBS patients had a significantly higher density of intestinal epithelial gaps. The elevated epithelial gaps in the intestine of IBS patients, a surrogate marker for increased epithelial cell extrusion, may be a cause of altered intestinal permeability observed and may lead to mucosal inflammation.
Confocal laser endomicroscopy (CLE) is a new endoscopic imaging tool enabling visualization of changes in the gut mucosa. The use of intravenous fluorescein enables high-resolution real-time imaging in vivo at a micron scale, allowing visualization of cellular details during ongoing endoscopy. This technology can be used to identify and quantify epithelial gaps and other signs of inflammation.
The purpose of this study is to evaluate the presence of microscopic inflammation previously demonstrated in patients with IBS, using pCLE. The determination of the exact areas of inflammation allows a direct biopsy in a more accurate way. This type of systematic may allow in the future to classify these patients not only symptomatically (constipation, diarrhea or mixed predominant IBS) but also according to their degree of inflammation. There is no Gold Standard test in these patients to assess response to treatment. The possibility of using pCLE to identify the areas of microscopic inflammation allows that the degree of inflammation can be used as a monitoring parameter. Probably the CLE can be used to assess response to treatment and different types of treatments, determining differences between subtypes of patients with IBS, evaluate remission, recurrence and prognosis. Also it may clarify a potential mechanism of the pathogenesis and be endoscopic criteria for the diagnosis of the disease.
The present study is the first to evaluate the colon microscopic inflammation using pCLE in IBS patients.
Study design: This is an observational and analytical cross-section, population - based survey study, with prospective case collection, non-randomized and simple blind, performed in a Tertiary Academic Center.
Setting: Ecuadorian Institute of Digestive Diseases (IECED), OmniHospital Academic Tertiary Center. We will include patients from October 2015 to March 2016. Patients will be recruited from the gastroenterology unit (IECED). The study protocol and consent form has been approved by the Institutional Review Board (IRB) and will be conducted according to the declaration of Helsinki. Patients will sign an informed consent and answer a questionnaire that includes constitutional data (sex, age, comorbid medical condition, medication). Patients in IBS group will be classified according to the symptoms as diarrhea predominant (IBS-D), constipation predominant (IBS-C) or mixed type (IBS-M). Endoscopic findings will be recorded in a database.
Endoscopic technique: All colonoscopies will be performed after the patient had undergone standard bowel preparation using either polyethylene glycol electrolyte lavage solution. Initially a routine white light colonoscopy will be performed in IBS and healthy control patients, using a Pentax scope (Pentax EC-387CILK, Tokyo, Japan) with great care not to damage the epithelium. The Boston Bowel Preparation Scale and inflammation changes will be recorded.
During withdrawal, all parts of the colon will be evaluated (cecum, right-side colon, transverse, left-side colon, sigmoid and rectum) using pCLE randomly in one point of each segment, if there are no signs of iatrogenic mucosal damage. Careful washing of the mucosa with water in order to prevent the inclusion of image artefacts from residual stool fragments. Before initiating CLE evaluation, intravenous injection of 5 ml 10% fluorescein will be done. Fluorescein stains vessels and gives good tissue structure, but the nuclei are not stained and appear as dark spots. Optimal contrast is obtained within the first 10min after injection, but good quality images can be acquired for a further 30-60 min.
Currently Confocal Laser Endomicroscopy (CLE) is performed using a CLE probe (pCLE). The confocal microscope used in pCLE captures microscopic images of untreated in vivo tissue. The microscope uses focused laser light of a defined wavelength and passes it through a confocal aperture. Images are then reconstructed in two dimensions. For pCLE (Cellvizio by Mauna Kea Technologies, Paris, France), both the laser scanning unit and light source are outside the body. The laser beam is transported via flexible confocal miniprobes and a distal lens sequentially scans it through a bundle of more than 10000 optical fibers. Confocal miniprobes are flexible, with diameters ranging from 0.9 mm to 2.5 mm.
In the study a pCLE ColoFlex probe will be used (Cellvizio; Mauna Kea Technology, Paris, France). The probe goes through the accessory channel of a conventional endoscope. The image rate is 0.08 s/frame at 1024×1024 pixels with a imaging depth of 20 μm. The confocal images will be first analyzed during the endoscopy. Then, the images will be digitally stored and reviewed after the procedure in order to zoom in on details for a higher magnification (approximately 10000 fold), with special designed software package (Cellvizio Viewer), allowing image correction and stabilization.
Immediately after pCLE evaluation, and before proceeding to the next colon segment, targeted biopsies will be taken from the mucosal area evaluated. Bleeding can impair image quality, therefore probe will be placed gently in contact with the tissue in order to avoid trauma and pCLE imaging will be completed in a region before mucosa biopsy. The endoscopist performing the pCLE will be blinded to the status of the patient and the images will be later analyzed in detail blindly by two different persons with more than two years' experience in endomicroscopy.
There are not studies that validate a classification of colon inflammation using CLE in IBS patients. Inflammation of the colon mucosa in ulcerative colitis (UC) has been described previously using CLE. Kiesslich et al. reported on a 3-grade classification of inflammation activity by CLE, combining crypt architecture, cellular infiltrations, and vessel architecture. Nevertheless the assessment of cellular infiltration has been questioned because of the difficulty in differentiating cell types by CLE. Chang-Qing Li, et al. used three CLE parameters to evaluate inflammation in UC patients: a 4-grade crypt-architecture classification, fluorescein leakage, and microvascular alterations. On the other hand, the Miami classification for pCLE defines colitis using: crypt fusion and distortion, bright epithelium, dilated and prominent branching vessels.In the present study the parameters used for CLE inflammation will be: 1.Epithelial gaps followed by leaks with secretion of fluorescein into the lumen. In CLE images of normal colonic mucosa, the lumen of the crypt is free of fluorescein and appears as a dark center in the crypt; however, in inflamed mucosa, fluorescein leaks into the crypt lumen; therefore, the lumen is brighter than the surrounding epithelium. 2.4-grade crypt-architecture classification: Types A and B will be considered as normal and chronic inflammation, respectively, and types C and D indicate acute inflammation. Type A: Regular arrangement and size of crypts. Type B: Irregular arrangement of crypts, enlarged spaces between crypts. Type C: Dilation of crypt openings, more irregular arrangement of crypts, and enlarged spaces between crypts as compared to type B. Type D: Crypt destruction and / or crypt abscess. 3.Dilated and prominent branching vessels
Interobserver and Intraobserver Agreement: A data set containing CLE photographs and videos of the all of the colon segments will be presented to three blinded endoscopists, who will confirm or not the findings. Inter- and intra-observer reproducibility will be measured based on comparison of still images and videos between the three investigators. To evaluate the intra-observer agreement each investigator will assess the images two times and the answers will be compared. To evaluate the inter-observer agreement all answers between the three investigators will be compared. In general, the learning curve of CLE is short and inter or intra-observer agreement is good.
Statistical analysis: Baseline characteristics will be compared between case and control group using Chi-square o Fisher Test for categorical variable, and for continuing variables, we will use the Mann-Whitney Test. Diagnosis efficacy will be measured thought sensitive, specificity and accuracy. All the statistical analysis will be performed using SPSS software suite v.22.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| IBS + Confocal Laser Endomicroscopy | – | Device: Confocal Laser EndomicroscopyOutpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test. |
| Control + Confocal Laser Endomicroscopy | – | Device: Confocal Laser EndomicroscopyOutpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: 1) Improvement with defecation, 2) Start associated with changes in the bowel frequency, 3) Start associated with changes in stool consistency. In the absence of alarm symptoms. It will be measured in all patients serology for celiac disease, serum thyroid-stimulating hormone (TSH) and parasitological test. It will be done, in high suspicion patients, stool culture, breath test for lactose intolerance and breath test for bacterial overgrowth.
Key inclusion criteria (4 listed)
- Above 18 years old patients
- Who agree to participate in the study
- Ability to provide written informed consent
- Patients with irritable bowel syndrome according to Roma III classification.
Key exclusion criteria (13 listed)
- Patients, who were receiving nonsteroidal anti-inflammatory drugs, corticosteroids or antibiotics in the last 4 weeks.
- Patients with heart disease, kidney, liver or severe metabolic disorder, who cannot tolerate sedation
- Inflammatory bowel disease
- Bacterial overgrowth
- Gastrointestinal bleeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Confocal Laser EndomicroscopyDuring colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels) | Device | Control + Confocal Laser Endomicroscopy, IBS + Confocal Laser Endomicroscopy |
Primary outcome
Confocal Laser Endomicroscopy (CLE) utility for diagnosing microscopic inflammation of the mucosa in patients with irritable bowel syndrome (IBS)
Time frame: four month
Number of patients with IBS and microscopic inflammation determinate by CLE
1 secondary outcome
Relationship between microscopic inflammation and sex, age and the subtypes of IBS.
Time frame: four month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2018.
- Results publication: PubMed 16678561Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061.
- Results publication: PubMed 16678553Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available.
- Results publication: PubMed 18420501Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008 Apr 17;358(16):1692-9. doi: 10.1056/NEJMcp0801447.
- Results publication: PubMed 12454866Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31. doi: 10.1053/gast.2002.37095. No abstract available.
- Results publication: PubMed 12454854Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):1972-9. doi: 10.1053/gast.2002.37059.
- Results publication: PubMed 18054549Kiesslich R, Goetz M, Angus EM, Hu Q, Guan Y, Potten C, Allen T, Neurath MF, Shroyer NF, Montrose MH, Watson AJ. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology. 2007 Dec;133(6):1769-78. doi: 10.1053/j.gastro.2007.09.011. Epub 2007 Sep 16.
- Results publication: PubMed 23357497Turcotte JF, Kao D, Mah SJ, Claggett B, Saltzman JR, Fedorak RN, Liu JJ. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc. 2013 Apr;77(4):624-30. doi: 10.1016/j.gie.2012.11.006. Epub 2013 Jan 26.
- Results publication: PubMed 25083606Fritscher-Ravens A, Schuppan D, Ellrichmann M, Schoch S, Rocken C, Brasch J, Bethge J, Bottner M, Klose J, Milla PJ. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1012-20.e4. doi: 10.1053/j.gastro.2014.07.046. Epub 2014 Jul 30.
- Results publication: PubMed 19136102Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009 Mar;69(3 Pt 2):620-5. doi: 10.1016/j.gie.2008.05.057. Epub 2009 Jan 10.
- Results publication: PubMed 22459661Kuiper T, Kiesslich R, Ponsioen C, Fockens P, Dekker E. The learning curve, accuracy, and interobserver agreement of endoscope-based confocal laser endomicroscopy for the differentiation of colorectal lesions. Gastrointest Endosc. 2012 Jun;75(6):1211-7. doi: 10.1016/j.gie.2012.01.040. Epub 2012 Mar 28.
- Results publication: PubMed 21818734Wallace M, Lauwers GY, Chen Y, Dekker E, Fockens P, Sharma P, Meining A. Miami classification for probe-based confocal laser endomicroscopy. Endoscopy. 2011 Oct;43(10):882-91. doi: 10.1055/s-0030-1256632. Epub 2011 Aug 4.
- Results publication: PubMed 18436217Becker V, von Delius S, Bajbouj M, Karagianni A, Schmid RM, Meining A. Intravenous application of fluorescein for confocal laser scanning microscopy: evaluation of contrast dynamics and image quality with increasing injection-to-imaging time. Gastrointest Endosc. 2008 Aug;68(2):319-23. doi: 10.1016/j.gie.2008.01.033. Epub 2008 Apr 24.
- Individual participant dataSharing planned: Undecided
Related trials for Irritable Bowel Syndrome (IBS)
RecruitingObservational study
Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and the Gut-Skin Axis
IBS (Irritable Bowel Syndrome), Rosacea
Recruiting
Stress Reduction and Lifestyle Modification in Irritable Bowel Syndrome Patients
Irritable Bowel Syndrome
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Irritable Bowel Syndrome, Constipation
RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Irritable Bowel Syndrome, Diarrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carlos A Robles-Medranda, MD principal investigator
Ecuadorian Institute of Digestive Diseases
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Irritable Bowel Syndrome (IBS), run by Instituto Ecuatoriano de Enfermedades Digestivas at 1 site in Ecuador.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ecuador. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Confocal Laser Endomicroscopy (CLE) utility for diagnosing microscopic inflammation of the mucosa in patients with irritable bowel syndrome (IBS) (time frame: four month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02651532, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2018.